tetano
Editor, Senior Moderator
Res Pract Thromb Haemost
. 2022 Jun 21;6(4):e12750.
doi: 10.1002/rth2.12750. eCollection 2022 May.
Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination
Rezvan Hosseinzadeh[SUP] 1 [/SUP], Mohammad Barary[SUP] 2 3 [/SUP], Hamed Mehdinezhad[SUP] 4 [/SUP], Terence T Sio[SUP] 5 [/SUP], Florian Langer[SUP] 6 [/SUP], Sahar Khosravi[SUP] 4 7 [/SUP]
Affiliations
Abstract
Background: Severe side effects after vaccination with coronavirus disease 2019 (COVID-19) vaccines are rare but can be fatal. To date, vaccine-induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID-19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine.
Key clinical question: The Key Clinical Question was to determine whether inactivated COVID-19 vaccines could induce VITT and how to diagnose and treat such cases.
Clinical approach and conclusions: Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti-heparin-platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high-dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant.
Keywords: COVID‐19; SARS‐CoV‐2; Sinopharm; VITT; thrombosis; vaccine.
. 2022 Jun 21;6(4):e12750.
doi: 10.1002/rth2.12750. eCollection 2022 May.
Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination
Rezvan Hosseinzadeh[SUP] 1 [/SUP], Mohammad Barary[SUP] 2 3 [/SUP], Hamed Mehdinezhad[SUP] 4 [/SUP], Terence T Sio[SUP] 5 [/SUP], Florian Langer[SUP] 6 [/SUP], Sahar Khosravi[SUP] 4 7 [/SUP]
Affiliations
- PMID: 35769629
- PMCID: PMC9210570
- DOI: 10.1002/rth2.12750
Abstract
Background: Severe side effects after vaccination with coronavirus disease 2019 (COVID-19) vaccines are rare but can be fatal. To date, vaccine-induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID-19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine.
Key clinical question: The Key Clinical Question was to determine whether inactivated COVID-19 vaccines could induce VITT and how to diagnose and treat such cases.
Clinical approach and conclusions: Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti-heparin-platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high-dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant.
Keywords: COVID‐19; SARS‐CoV‐2; Sinopharm; VITT; thrombosis; vaccine.